Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

  • End date
    May 30, 2025
  • participants needed
  • sponsor
    Roswell Park Cancer Institute
Updated on 30 May 2022
platelet count
measurable disease
neutrophil count
tumor cells


This early phase I trial studies the direct effects on cancer cells of the drugs binimetinib and palbociclib, in patients with KRAS-positive lung, colorectal, or pancreatic cancer that can be removed by surgery (operable). Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and palbociclib may halt the growth of cancer cells and improve access of the immune system cells, a patient's own cells that fight infection and cancer, into the tumor.



I. To determine the on-target efficacy of binimetinib and palbociclib in patients with operable RAS-mutant lung adenocarcinoma, colorectal, or pancreatic cancer.


I. Correlative analysis of gene expression analysis. II. Define immune subsets within the pre and post-treatment tumor tissue.


Patients receive palbociclib orally (PO) once daily (QD) and binimetinib PO twice daily (BID) for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week after last dose of study medication, patients undergo surgery.

After completion of study treatment, patients are followed up at 30 days.

Condition Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
Treatment therapeutic conventional surgery, Palbociclib, Binimetinib
Clinical Study IdentifierNCT04870034
SponsorRoswell Park Cancer Institute
Last Modified on30 May 2022


Yes No Not Sure

Inclusion Criteria

Age >= 18 years of age
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Patients with verified and operable KRAS-positive mutant lung adenocarcinoma, colorectal, or pancreatic cancer
Have available diagnostic, pre-treatment archival tumor tissue
Medically fit for surgical resection
Absolute neutrophil count (ANC) >= 1500/ uL
Hemoglobin (Hgb) >= 9 g/dL
Platelet count >= 100,000/uL
Total bilirubin =< 1.5 x ULN (upper limit of normal)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN
Creatinine clearance > 60 mL/min (Cockcroft-Gault Equation)
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
Ability to swallow and retain oral medication
Female participants of childbearing potential must agree to use methods of contraception that are highly effective or acceptable, and to not donate ova from screening until 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Male participants must agree to use methods of contraception that are highly effective or acceptable, and to not donate sperm from screening until 90 days after the last dose of study drug
Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria

Prior therapy with a CDK4/6 (e.g. palbociclib, ribociclib) or MEK inhibitor (e.g., binimetinib, trametinib, cobimetinib)
Participants who have had any other systemic anticancer therapy within 2 weeks prior to entering the study
Is currently participating in a study and receiving an investigational agent; has received an investigational agent within 14 days prior to start of study treatment
Participants who have undergone major surgery =< 6 weeks prior to start of study treatment or who have not recovered from side effects of such procedure
Patient has not recovered to =< grade 1 from toxic effects of prior therapy before starting study treatment. Note: Stable chronic conditions (=< grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related endocrinopathies) are exceptions and may enroll
Uncontrolled or symptomatic brain metastases or leptomeningeal carcinomatosis that are not stable, require steroids, are potentially life-threatening or have required radiation within 28 days prior to starting study drug. Note: Patients with previously treated brain metastases may participate provided they are stable (e.g., without evidence of progression by radiographic imaging for at least 28 days before the first dose of study treatment and neurologic symptoms have returned to baseline), and have no evidence of new or enlarging brain metastases or central nervous system (CNS) edema, and does not require steroids at least 7 days before the first dose of study treatment
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Impaired cardiovascular function or clinically significant cardiac diseases including, but not limited to, any of the following
History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) < 6 months prior to screening
Congestive heart failure requiring treatment (New York Heart Association grade >= 2)
Left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition scan (MUGA) or echocardiography (ECHO)
Uncontrolled hypertension defined as persistent systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100 mmHg despite current therapy
History or presence of clinically significant cardiac arrhythmias (including resting bradycardia, uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia)
Baseline corrected QT (QTc) interval >= 480 ms
Impairment of gastrointestinal function or disease which may significantly alter the
absorption of binimetinib or palbociclib (e.g., active ulcerative disease
uncontrolled vomiting or diarrhea, malabsorption syndrome, small bowel
resection with decreased intestinal absorption), or recent (=< 3 months)
history of a partial or complete bowel obstruction, or other conditions that
will interfere significantly with the absorption of oral drugs
Patients who have neuromuscular disorders that are associated with elevated creatine kinase (CPK) (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
History or current evidence of retinal vein occlusion (RVO) or current risk factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
Current use of a prohibited medication (including herbal medications, supplements, or foods) or use of a prohibited medication =< 1 week prior to the start of study treatment
History of or cerebrovascular events =< 12 weeks prior to the first dose of study treatment
History of pulmonary embolism (PE) with hemodynamic instability =< 12 weeks prior to first dose of study treatment. Note: Patients with PE that does not result in hemodynamic instability are allowed to enroll as long as they are on a stable dose of therapeutic anticoagulants for at least 4 weeks. Also, patients with deep vein thrombosis on stable dose of therapeutic anticoagulants for at least 4 weeks are allowed to participate in the study
Concurrent or previous other malignancy that requires active anticancer therapy
Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Note: Patients with laboratory evidence of cleared HBV or HCV infection may be enrolled
Note: Patients with no prior history of HBV infection who have been vaccinated against HBV and who have a positive antibody against hepatitis B surface antigen as the only evidence of prior exposure may be enrolled
Known history of acute or chronic pancreatitis =< 6 months prior to enrollment
History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) =< 12 months prior to enrollment
Known hypersensitivity to the components of study drugs or its analogs
Pregnant or nursing female participants
Unwilling or unable to follow protocol requirements
Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient an inappropriate candidate for the study
The following special populations will not be included in the study
Cognitively impaired adults/adults with impaired decision-making capacity
Individuals who are not yet adults (infants, children, teenagers)
Pregnant women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note